Lyka Labs Limited (IN:LYKALABS)
:LYKALABS
Want to see IN:LYKALABS full AI Analyst Report?
LYKALABS Stock Chart & Stats
₹94.40
-₹1.55(-0.97%)
At close: 4:00 PM EST
₹94.40
-₹1.55(-0.97%)
Day’s Range― - ―
52-Week Range₹44.49 - ₹121.00
Previous CloseN/A
Volume78.41K
Average Volume (3M)3.02K
Market Cap
₹2.51B
Enterprise Value₹2.99B
Total Cash (Recent Filing)₹11.89M
Total Debt (Recent Filing)₹316.57M
Price to Earnings (P/E)―
Beta1.46
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.55
Shares Outstanding35,690,000
10 Day Avg. Volume1,252
30 Day Avg. Volume3,017
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)1.74
Price to Sales (P/S)1.25
P/FCF Ratio-21.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Leverage ReductionThe material reduction in gross debt materially lowers refinancing and interest-rate risk and increases financial flexibility. Over a 2–6 month horizon this strengthens the firm’s ability to fund operations, pursue selective capex or absorb shocks while management stabilizes profitability.
Positive Operating Cash FlowSustained positive operating cash flow indicates core pharmaceutical operations generate cash even amid accounting losses. This durable cash inflow supports working capital, ongoing manufacturing activity and limits immediate liquidity strain while management focuses on restoring profitability.
Integrated API And Formulations ModelA vertically integrated product mix (APIs and finished formulations) and exposure to domestic and export channels provide diversified revenue pathways. This structural business model supports resilience to single-segment shocks and enables cross-selling and margin improvement opportunities over the medium term.
Bears Say
Revenue Decline And Net LossThe sharp year-over-year revenue drop and swing to a sizeable net loss reflect unstable demand or cost control issues. Such swings impair earnings quality, make multi-quarter recovery uncertain and weaken the company’s ability to reinvest or absorb adverse tender and pricing dynamics.
Consistently Negative Free Cash FlowPersistent negative free cash flow signals the business cannot fully self-finance capex or working capital needs, increasing reliance on external funding. Over months this constrains strategic flexibility, raises refinancing risk and could limit investment in capacity or new product development.
Historical Earnings Instability And Past High LeveragePrior episodes of extreme leverage and even negative equity indicate structural volatility in capital and earnings. That legacy raises counterparty and investor confidence risk, making durable access to capital and large strategic partnerships more difficult until sustained profitability is proven.
Lyka Labs Limited News
LYKALABS FAQ
What was Lyka Labs Limited’s price range in the past 12 months?
Lyka Labs Limited lowest stock price was ₹44.49 and its highest was ₹121.00 in the past 12 months.
What is Lyka Labs Limited’s market cap?
Lyka Labs Limited’s market cap is ₹2.51B.
When is Lyka Labs Limited’s upcoming earnings report date?
Lyka Labs Limited’s upcoming earnings report date is Aug 07, 2026 which is in 49 days.
How were Lyka Labs Limited’s earnings last quarter?
Lyka Labs Limited released its earnings results on May 25, 2026. The company reported -₹2.13 earnings per share for the quarter, missing the consensus estimate of N/A by -₹2.13.
Is Lyka Labs Limited overvalued?
According to Wall Street analysts Lyka Labs Limited’s price is currently Overvalued.
Does Lyka Labs Limited pay dividends?
Lyka Labs Limited does not currently pay dividends.
What is Lyka Labs Limited’s EPS estimate?
Lyka Labs Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lyka Labs Limited have?
Lyka Labs Limited has 35,690,000 shares outstanding.
What happened to Lyka Labs Limited’s price movement after its last earnings report?
Lyka Labs Limited reported an EPS of -₹2.13 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.162%.
Which hedge fund is a major shareholder of Lyka Labs Limited?
Currently, no hedge funds are holding shares in IN:LYKALABS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lyka Labs Limited
Established in 1976 and headquartered in Mumbai, India, Lyka Labs Limited is a pharmaceutical firm specializing in the development, manufacturing, and marketing of a wide array of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company's extensive product portfolio addresses numerous therapeutic areas, including intensive care, gastroenterology, anti-infectives, anti-fungals, surgery, urology, wound care, anesthesia, and various dermatological and cosmeceutical applications like topical steroids, anti-acne, anti-aging, and hair care. These products are available in diverse forms, such as injections, creams, ointments, gels, and lotions. Beyond its own offerings, Lyka Labs also provides contract manufacturing services to other major pharmaceutical companies and offers comprehensive medical and technical support. This support includes manufacturing expertise, facility assistance, and crucial technical data such as molecule stability testing, impurity profiling, and bioequivalence (BA/BE) clinical study data. The company's market reach extends globally, with exports to various countries including Bangladesh, Cambodia, Congo, Costa Rica, Peru, Romania, Russia, Sri Lanka, Sudan, Ukraine, Venezuela, and Vietnam.
Technical Analysis
Dishman Carbogen Amcis Ltd.
―
Panacea Biotec Limited
―
SMS Lifesciences India Ltd.
―
Supriya Lifescience Limited
―
Zota Health Care Ltd.
―